PIRS Stock - Pieris Pharmaceuticals, Inc.
Unlock GoAI Insights for PIRS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $42.81M | $25.90M | $31.42M | $29.32M |
| Gross Profit | N/A | $1.01M | $23.12M | $29.05M | $-17,208,000 |
| Gross Margin | N/A | 2.4% | 89.3% | 92.5% | -58.7% |
| Operating Income | N/A | $-29,756,000 | $-43,474,000 | $-51,831,000 | $-33,921,000 |
| Net Income | $-17,434,000 | $-24,543,000 | $-31,253,000 | $-43,366,000 | $-37,230,000 |
| Net Margin | N/A | -57.3% | -120.7% | -138.0% | -127.0% |
| EPS | $-7.83 | $-21.80 | $-33.71 | $-53.75 | $-54.67 |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Visit WebsiteEarnings History & Surprises
PIRSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 11, 2025 | — | $-1.03 | — | — |
Q3 2025 | Aug 12, 2025 | — | $-0.86 | — | — |
Q2 2025 | May 13, 2025 | — | $-74.32 | — | — |
Q4 2024 | Nov 13, 2024 | $-4.00 | $-2.19 | +45.3% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-2.40 | $-2.76 | -15.0% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.12 | $-3.95 | -3191.7% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-9.60 | $-4.00 | +58.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-8.80 | $-8.80 | 0.0% | = MET |
Q3 2023 | Aug 10, 2023 | $-12.80 | $4.00 | +131.3% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-11.20 | $-14.40 | -28.6% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-10.40 | $-8.80 | +15.4% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-12.80 | $-10.40 | +18.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-8.80 | $-11.20 | -27.3% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-9.60 | $-5.60 | +41.7% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-24.00 | $-10.40 | +56.7% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-19.20 | $-19.20 | 0.0% | = MET |
Q3 2021 | Aug 4, 2021 | $-16.00 | $-20.00 | -25.0% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-13.60 | $-5.60 | +58.8% | ✓ BEAT |
Q1 2021 | Mar 30, 2021 | $-19.20 | $-20.80 | -8.3% | ✗ MISS |
Q4 2020 | Nov 4, 2020 | $-12.80 | $-20.80 | -62.5% | ✗ MISS |
Latest News
Frequently Asked Questions about PIRS
What is PIRS's current stock price?
What is the analyst price target for PIRS?
What sector is Pieris Pharmaceuticals, Inc. in?
What is PIRS's market cap?
Does PIRS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PIRS for comparison